# Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)

> **NCT02152956** · PHASE1,PHASE2 · TERMINATED · sponsor: **MacroGenics** · enrollment: 244 (actual)

## Conditions studied

- AML

## Interventions

- **BIOLOGICAL:** Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off
- **BIOLOGICAL:** Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off
- **BIOLOGICAL:** Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off
- **BIOLOGICAL:** Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off
- **BIOLOGICAL:** Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose
- **BIOLOGICAL:** Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose
- **BIOLOGICAL:** Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose
- **BIOLOGICAL:** Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose
- **BIOLOGICAL:** Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose
- **DRUG:** Ruxolitinib
- **BIOLOGICAL:** Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose

## Key facts

- **NCT ID:** NCT02152956
- **Lead sponsor:** MacroGenics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-06-09
- **Primary completion:** 2022-07-05
- **Final completion:** 2022-07-05
- **Target enrollment:** 244 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2024-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02152956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02152956, "Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT02152956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*